相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
Xiaolei Li et al.
ONCOGENE (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pancancer survival analysis of cancer hallmark genes
Adam Nagy et al.
SCIENTIFIC REPORTS (2021)
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
Hope S. Rugo et al.
ADVANCES IN THERAPY (2020)
Tumor microenvironment complexity and therapeutic implications at a glance
Roghayyeh Baghba et al.
CELL COMMUNICATION AND SIGNALING (2020)
The SWI/SNF complex in cancer - biology, biomarkers and therapy
Priya Mittal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
The application of histone deacetylases inhibitors in glioblastoma
Rui Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Marie-Lisa Eich et al.
CANCER RESEARCH (2020)
The tumor microenvironment
Nicole M. Anderson et al.
CURRENT BIOLOGY (2020)
A DNA methylation-based test for esophageal cancer detection
Sofia Salta et al.
BIOMARKER RESEARCH (2020)
EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells
Shuo Huang et al.
CANCER RESEARCH (2019)
Examining the effects of BET, HDAC2, and EZH2 inhibition on esophageal adenocarcinoma (EAC) cell line proliferation.
Kleovoulos Kofonikolas et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
Alexander M. Frankell et al.
NATURE GENETICS (2019)
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
F. Morschhauser et al.
HEMATOLOGICAL ONCOLOGY (2019)
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
Oliver Butters et al.
FRONTIERS IN ONCOLOGY (2019)
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2019)
EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
Dongwei Dou et al.
ONCOTARGETS AND THERAPY (2019)
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Xiaofu Qiu et al.
BMC CANCER (2019)
Epigenetic modifications of histones in cancer
Zibo Zhao et al.
GENOME BIOLOGY (2019)
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
HDAC inhibitors as epigenetic regulators for cancer immunotherapy
Mariarosaria Conte et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma
Paul L. Feingold et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study
Joonas H. Kauppila et al.
BMJ OPEN (2018)
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
David Wang et al.
CELL REPORTS (2018)
Cancer epigenetics: Moving forward
Angela Nebbioso et al.
PLOS GENETICS (2018)
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Dagmar Kollmann et al.
ONCOIMMUNOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
Marjorie Glass Zauderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma
Ines Lohse et al.
PLOS ONE (2018)
Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells
Youping Yang et al.
ONCOTARGETS AND THERAPY (2018)
EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression
Chenyu Wang et al.
ONCOTARGETS AND THERAPY (2018)
SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
Shuai Wu et al.
NATURE COMMUNICATIONS (2018)
c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Angela Nebbioso et al.
CLINICAL CANCER RESEARCH (2017)
Individual patient oesophageal cancer 3D models for tailored treatment
John H. Saunders et al.
ONCOTARGET (2017)
Histone Deacetylase Inhibitors as Anticancer Drugs
Tomas Eckschlager et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions
Katrin Bose et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Manuela Terranova-Barberio et al.
ONCOTARGET (2017)
Oesophageal cancer
Elizabeth C. Smyth et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
F. Noble et al.
BRITISH JOURNAL OF SURGERY (2017)
Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030
Melina Arnold et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
The tumor microenvironment in esophageal cancer
E. W. Lin et al.
ONCOGENE (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin's lymphomas (NHL), multiple myeloma (MM) and solid tumor.
Timothy Anthony Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine
Theresa D. Ahrens et al.
EPIGENETICS (2015)
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids
Quaovi H. Sodji et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma
Timothy J. Underwood et al.
JOURNAL OF PATHOLOGY (2015)
Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization
Carina Fischer et al.
MOLECULAR CANCER (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity
Jie Yin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
Bryson W. Katona et al.
CANCER BIOLOGY & THERAPY (2014)
The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer
Jian Wang et al.
CANCER BIOLOGY & THERAPY (2014)
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
J. Minami et al.
LEUKEMIA (2014)
Histone core modifications regulating nucleosome structure and dynamics
Peter Tessarz et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Epigenetic regulation and cancer ( Review)
Q. W. Chen et al.
ONCOLOGY REPORTS (2014)
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Sarah K. Knutson et al.
PLOS ONE (2014)
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis
Tomoharu Miyashita et al.
ONCOLOGY LETTERS (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
BELINOSTAT FOR THE TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS
J. McDermott et al.
DRUGS OF TODAY (2014)
Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells
Linda Marek et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
SET for life biochemical activities and biological functions of SET domain-containing proteins
Hans-Martin Herz et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Role of interleukin-6 in Barrett's esophagus pathogenesis
Katerina Dvorak et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Analysis of Esophageal Cancer Time Trends in China, 1989-2008
Jun Zhao et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan et al.
CANCER CELL (2012)
Oesophageal cancer survival in Europe: A EUROCARE-4 study
A. T. Gavin et al.
CANCER EPIDEMIOLOGY (2012)
Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release
Padmini Jayaraman et al.
JOURNAL OF IMMUNOLOGY (2012)
Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer A SEER Database Analysis
Attila Dubecz et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Breast Cancer Cells Induce Stromal Fibroblasts to Secrete ADAMTS1 for Cancer Invasion through an Epigenetic Change
Shiaw-Wei Tyan et al.
PLOS ONE (2012)
Romidepsin: A New Drug for the Treatment of Cutaneous T-Cell Lymphoma
Robin Frye et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2012)
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Euan A. Stronach et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study
Rupert Langer et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription
Liling Tang et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2010)
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005
M. B. Cook et al.
BRITISH JOURNAL OF CANCER (2009)
Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression
Junko Suzuki et al.
CLINICAL CANCER RESEARCH (2009)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity
Mohan R. Kaadige et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Epigenetics: Definition, Mechanisms and Clinical Perspective
Catherine Dupont et al.
SEMINARS IN REPRODUCTIVE MEDICINE (2009)
Recent advances in three-dimensional multicellular spheroid culture for biomedical research
Ruei-Zhen Lin et al.
Biotechnology Journal (2008)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
S. Balasubramanian et al.
LEUKEMIA (2008)
Trends in oesophageal cancer incidence and mortality in Europe
Cristina Bosetti et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
MYC - TIMELINE Reflecting on 25 years with MYC
Natalie Meyer et al.
NATURE REVIEWS CANCER (2008)
From cancer immunosurveillance to cancer immunotherapy
John Stagg et al.
IMMUNOLOGICAL REVIEWS (2007)
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host
Cunren Liu et al.
BLOOD (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Methylation in esophageal carcinogenesis
Da-Long Wu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression
Burkhard H. A. von Rahden et al.
NEOPLASIA (2006)
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
BE Bernstein et al.
CELL (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
The key to development: interpreting the histone code?
R Margueron et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Histone metabolic pathways and chromatin assembly factors as proliferation markers
SE Polo et al.
CANCER LETTERS (2005)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
P Zhu et al.
CANCER CELL (2004)
Identification of genes that are regulated transcriptionally by Myc in childhood tumors
EA Raetz et al.
CANCER (2003)
Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin
B Lehnertz et al.
CURRENT BIOLOGY (2003)
Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro
C Tselepis et al.
GUT (2003)
Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: Role in epithelial cancer cell invasion, proliferation and nuclear regulation
GL Nicolson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Active genes are tri-methylated at K4 of histone H3
H Santos-Rosa et al.
NATURE (2002)
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism
A Mazzoni et al.
JOURNAL OF IMMUNOLOGY (2002)
Deacetylation of p53 modulates its effect on cell growth and apoptosis
JY Luo et al.
NATURE (2000)
分享论文
